Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.
Director Immune Therapy Development Center, TRON, VP, Immunotherapy and Preclinical Research at BioNTech RNA Pharmaceuticals
Sebastian Kreiter (M.D.) graduated in Medicine from the Johannes Gutenberg University in Mainz (Germany). Clinical training in hematology and oncology led him to translational science in the field of immunotherapies. Currently he is Director of the Immune Therapy Development Center at TRON - Translational Oncology at the Johannes Gutenberg University in Mainz (http://tron-mainz.de/) and Vice President Immunotherapy & Preclinical Research of BioNTech RNA Pharmaceuticals (http://biontech.de/). Aside from this, he serves as board member for the Association for Cancer Immunotherapy – CIMT (http://www.cimt.eu/home). Early efforts focused on preclinical development of in-vitro transcribed mRNA cancer vaccination, which is currently under clinical testing. More recently, he took part in the pioneering development of actively personalized cancer vaccination where jointly with Ugur Sahin he worked out the scientific and technical PoC for an mRNA based mutanome vaccine in murine model systems together with his team.